CYBN insider trading
Helus Pharma Inc.: insider trade history from SEC Form 4 filings.
CYBN insider activity at a glance
FilingIQ tracks 8 insider transactions for CYBN in filings since Sep 9, 2026. The most recent transaction is dated Sep 21, 2026.
Across the full history, 8 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest CYBN Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Most active insiders at CYBN
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for CYBN?
- FilingIQ tracks 8 Form 4 insider transactions for CYBN (Helus Pharma Inc.), covering filings from Sep 9, 2026 onwards. 8 of those are dated within the last 90 days.
- Are CYBN insiders net buyers or net sellers?
- Across the full Form 4 history for CYBN, 8 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CYBN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
Methodology & sources
Every CYBN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.